INBRAIN Neuroelectronics, member of CATALONIA.HEALTH, has announced the world's first application of a graphene interface in a human patient. This intervention was performed on a patient undergoing resection (removal) of a brain tumor. The company is a spin-off of ICN2 and CSIC.
INBRAIN's brain-computer interfaces (BCI) technology was used to help the surgeon perform a more precise resection by accurately monitoring brain activity and helping to distinguish between cancerous and healthy tissue. The procedure is part of a clinical study sponsored by the University of Manchester.
This achievement shows the enormous potential of BCI technology, which goes beyond decoding and translating brain signals. This technology has become a powerful tool for precision surgery. The implant developed by INBRAIN exploits graphene's unique electronic and mechanical properties, making it ideal for innovation in neurotechnology.
According to Carolina Aguilar, CEO and Co-Founder of INBRAIN, "This first human application of graphene-based BCI technology opens a new era for these technologies, opening the way for further advances in both neural decoding and therapeutic applications. INBRAIN is at the forefront of precision neurology, integrating BCI decoding with high-precision neuromodulation to restore function and minimize adverse patient events.”
Comments